MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager
Starting year
2022
Granted funding
Saru Basnet
4 000 €
Funder
The Paulo Foundation
Other information
Funding decision number
A1537
Keywords
Lääketiede
Identified topics
cancer